Cargando…
Diagnostic and prognostic role of liquid biopsy in non-small cell lung cancer: evaluation of circulating biomarkers
Lung cancer is still one of the main causes of cancer-related death, together with prostate and colorectal cancers in males and breast and colorectal cancers in females. The prognosis for non-small cell lung cancer (NSCLC) is strictly dependent on feasibility of a complete surgical resection of the...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Open Exploration
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400689/ https://www.ncbi.nlm.nih.gov/pubmed/36046486 http://dx.doi.org/10.37349/etat.2020.00020 |
_version_ | 1784772797159964672 |
---|---|
author | Vicidomini, Giovanni Cascone, Roberto Carlucci, Annalisa Fiorelli, Alfonso Di Domenico, Marina Santini, Mario |
author_facet | Vicidomini, Giovanni Cascone, Roberto Carlucci, Annalisa Fiorelli, Alfonso Di Domenico, Marina Santini, Mario |
author_sort | Vicidomini, Giovanni |
collection | PubMed |
description | Lung cancer is still one of the main causes of cancer-related death, together with prostate and colorectal cancers in males and breast and colorectal cancers in females. The prognosis for non-small cell lung cancer (NSCLC) is strictly dependent on feasibility of a complete surgical resection of the tumor at diagnosis. Since surgery is indicated only in early stages tumors, it is necessary to anticipate the timing of diagnosis in clinical practice. In the diagnostic and therapeutic pathway for NSCLC, sampling of neoplastic tissue is usually obtained using invasive methods that are not free from disadvantages and complications. A valid alternative to the standard biopsy is the liquid biopsy (LB), that is, the analysis of samples from peripheral blood, urine, and other biological fluids, with a simple and non-invasive collection. In particular, it is possible to detect in the blood different tumor derivatives, such as cell-free DNA (cfDNA) with its subtype circulating tumor DNA (ctDNA), cell-free RNA (cfRNA), and circulating tumor cells (CTCs). Plasma-based testing seems to have several advantages over tumor tissue biopsy; firstly, it reduces medical costs, risk of complications related to invasive procedures, and turnaround times; moreover, the analysis of genes alteration, such as EGFR, ALK, ROS1, and BRAF is faster and safer with this method, compared to tissue biopsy. Despite all these advantages, the evidences in literatures indicate that assays performed on liquid biopsies have a low sensitivity, making them unsuitable for screening in lung cancer at the current state. This is caused by lack of standardization in sampling and preparation of specimen and by the low concentration of biomarkers in the bloodstream. Instead, routinely use of LB should be preferred in revaluation of patients with advanced NSCLC resistant to chemotherapy, due to onset of new mutations. |
format | Online Article Text |
id | pubmed-9400689 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Open Exploration |
record_format | MEDLINE/PubMed |
spelling | pubmed-94006892022-08-30 Diagnostic and prognostic role of liquid biopsy in non-small cell lung cancer: evaluation of circulating biomarkers Vicidomini, Giovanni Cascone, Roberto Carlucci, Annalisa Fiorelli, Alfonso Di Domenico, Marina Santini, Mario Explor Target Antitumor Ther Review Lung cancer is still one of the main causes of cancer-related death, together with prostate and colorectal cancers in males and breast and colorectal cancers in females. The prognosis for non-small cell lung cancer (NSCLC) is strictly dependent on feasibility of a complete surgical resection of the tumor at diagnosis. Since surgery is indicated only in early stages tumors, it is necessary to anticipate the timing of diagnosis in clinical practice. In the diagnostic and therapeutic pathway for NSCLC, sampling of neoplastic tissue is usually obtained using invasive methods that are not free from disadvantages and complications. A valid alternative to the standard biopsy is the liquid biopsy (LB), that is, the analysis of samples from peripheral blood, urine, and other biological fluids, with a simple and non-invasive collection. In particular, it is possible to detect in the blood different tumor derivatives, such as cell-free DNA (cfDNA) with its subtype circulating tumor DNA (ctDNA), cell-free RNA (cfRNA), and circulating tumor cells (CTCs). Plasma-based testing seems to have several advantages over tumor tissue biopsy; firstly, it reduces medical costs, risk of complications related to invasive procedures, and turnaround times; moreover, the analysis of genes alteration, such as EGFR, ALK, ROS1, and BRAF is faster and safer with this method, compared to tissue biopsy. Despite all these advantages, the evidences in literatures indicate that assays performed on liquid biopsies have a low sensitivity, making them unsuitable for screening in lung cancer at the current state. This is caused by lack of standardization in sampling and preparation of specimen and by the low concentration of biomarkers in the bloodstream. Instead, routinely use of LB should be preferred in revaluation of patients with advanced NSCLC resistant to chemotherapy, due to onset of new mutations. Open Exploration 2020 2020-10-30 /pmc/articles/PMC9400689/ /pubmed/36046486 http://dx.doi.org/10.37349/etat.2020.00020 Text en © The Author(s) 2020. https://creativecommons.org/licenses/by/4.0/This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Vicidomini, Giovanni Cascone, Roberto Carlucci, Annalisa Fiorelli, Alfonso Di Domenico, Marina Santini, Mario Diagnostic and prognostic role of liquid biopsy in non-small cell lung cancer: evaluation of circulating biomarkers |
title | Diagnostic and prognostic role of liquid biopsy in non-small cell lung cancer: evaluation of circulating biomarkers |
title_full | Diagnostic and prognostic role of liquid biopsy in non-small cell lung cancer: evaluation of circulating biomarkers |
title_fullStr | Diagnostic and prognostic role of liquid biopsy in non-small cell lung cancer: evaluation of circulating biomarkers |
title_full_unstemmed | Diagnostic and prognostic role of liquid biopsy in non-small cell lung cancer: evaluation of circulating biomarkers |
title_short | Diagnostic and prognostic role of liquid biopsy in non-small cell lung cancer: evaluation of circulating biomarkers |
title_sort | diagnostic and prognostic role of liquid biopsy in non-small cell lung cancer: evaluation of circulating biomarkers |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400689/ https://www.ncbi.nlm.nih.gov/pubmed/36046486 http://dx.doi.org/10.37349/etat.2020.00020 |
work_keys_str_mv | AT vicidominigiovanni diagnosticandprognosticroleofliquidbiopsyinnonsmallcelllungcancerevaluationofcirculatingbiomarkers AT casconeroberto diagnosticandprognosticroleofliquidbiopsyinnonsmallcelllungcancerevaluationofcirculatingbiomarkers AT carlucciannalisa diagnosticandprognosticroleofliquidbiopsyinnonsmallcelllungcancerevaluationofcirculatingbiomarkers AT fiorellialfonso diagnosticandprognosticroleofliquidbiopsyinnonsmallcelllungcancerevaluationofcirculatingbiomarkers AT didomenicomarina diagnosticandprognosticroleofliquidbiopsyinnonsmallcelllungcancerevaluationofcirculatingbiomarkers AT santinimario diagnosticandprognosticroleofliquidbiopsyinnonsmallcelllungcancerevaluationofcirculatingbiomarkers |